Overcoming Biosimilar Scaling Challenges: Process consistency and robustness, analytical excellence, and regulatory compliance are essential in the scale-up of biosimilars.
| Publicado en: | BioPharm International Vol. 38; no. 3; pp. 18 - 21 |
|---|---|
| Autor principal: | |
| Formato: | pictorial Journal Article |
| Publicado: |
MJH Life Sciences
Apr2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=184485597&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 184485597 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1542166X 5NE jtl: BioPharm International issn: 1542166X maglogo: N pubinfo: dt: Apr2025 vid: 38 iid: 3 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 184485597 184485597 184485597 184485597 ppf: 18 ppct: 3 formats: fmt: @attributes: type: P tig: atl: Overcoming Biosimilar Scaling Challenges: Process consistency and robustness, analytical excellence, and regulatory compliance are essential in the scale-up of biosimilars. aug: au: CHALLENER, CYNTHIA A. sug: subj: Biosimilar Pharmaceuticals Economics Pharmaceutical Companies Productivity Organizational Compliance Chemistry, Analytical Drug Approval United States Food and Drug Administration Marketing Environmental Monitoring pubtype: Trade Publication doctype: pictorial Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|